List View

By /

Clear

Displaying 2,601 - 2,625 of 2,995

Addressing Disparities in Access to Supportive Care During Cancer Treatment and Survivorship: An Integrative Approach

Addressing Disparities in Access to Supportive Care During Cancer Treatment and Survivorship: An Integrative Approach

Upper GI Cancer: Esophageal and Gastric-New Developments

Upper GI Cancer: Esophageal and Gastric-New Developments

Pancreas, Hepatic and Cholangiocarcinoma: Advances in 2024

Pancreas, Hepatic and Cholangiocarcinoma: Advances in 2024

Colorectal Cancer: Novel Treatment Paradigms

Colorectal Cancer: Novel Treatment Paradigms

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor)

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor)

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against)

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against)

Melanoma: Novel Advances in Immunotherapy

Melanoma: Novel Advances in Immunotherapy

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

End of Life Management: Oncologists’ Perspectives

End of Life Management: Oncologists’ Perspectives

Lifestyle Modifications in Reducing Risk of Recurrence

Lifestyle Modifications in Reducing Risk of Recurrence

Artificial Intelligence and Modern Medical Practice: Do’s and Don’ts

Artificial Intelligence and Modern Medical Practice: Do’s and Don’ts

Soft Tissue and Osteosarcomas: Novel Advances in 2024

Soft Tissue and Osteosarcomas: Novel Advances in 2024

Novel Advances for Thyroid Carcinoma and Thymoma

Novel Advances for Thyroid Carcinoma and Thymoma

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

ctDNA in Lung Cancer: Current State and Future Perspectives

ctDNA in Lung Cancer: Current State and Future Perspectives

Challenges in Lung Cancer Pathology: Biomarkers

Challenges in Lung Cancer Pathology: Biomarkers

Screening in Lung Cancer: Challenges and Obstacles

Screening in Lung Cancer: Challenges and Obstacles

Optimal Surgical Approach in Early Stages NSCLC

Optimal Surgical Approach in Early Stages NSCLC

Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy

Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy

What Is Next After Osimertinib Progression?

What Is Next After Osimertinib Progression?